Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Top Owners Are Retail Investors With 58% Stake, While 26% Is Held by Institutions
Press Release: Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
H.C. Wainwright Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $15
Express News | Eton Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $15 From $11
Eton Pharmaceuticals Has Acquired The Us Rights To Amglidia (Glyburide Oral Suspension, Known As Glibenclamide In Europe) For Neonatal Diabetes Mellitus From AMMTeK, Potential US Marketing Application Submission Expected In 2026
